Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
134.5 EUR | -0.22% | +0.99% | +43.70% |
06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
06-28 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Sales 2024 * | 292B 41.98B 39.07B 3,320B | Sales 2025 * | 352B 50.74B 47.21B 4,013B | Capitalization | 4,460B 642B 598B 50,786B |
---|---|---|---|---|---|
Net income 2024 * | 104B 15.02B 13.98B 1,188B | Net income 2025 * | 128B 18.42B 17.14B 1,457B | EV / Sales 2024 * | 15.4 x |
Net Debt 2024 * | 22.58B 3.25B 3.02B 257B | Net cash position 2025 * | 5.93B 854M 794M 67.51B | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
43.3
x | P/E ratio 2025 * |
35.2
x | Employees | 66,015 |
Yield 2024 * |
1.17% | Yield 2025 * |
1.44% | Free-Float | 70.22% |
Latest transcript on Novo Nordisk A/S
1 day | -0.22% | ||
1 week | +0.99% | ||
Current month | +7.62% | ||
1 month | +9.00% | ||
3 months | +12.08% | ||
6 months | +43.70% | ||
Current year | +43.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 31/12/90 | |
Director of Finance/CFO | 53 | 31/12/98 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 18/03/15 |
Helge Lund
CHM | Chairman | 62 | 22/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 28/02/18 |
Date | Price | Change | Volume |
---|---|---|---|
28/06/24 | 134.5 | -0.22% | 8,835 |
27/06/24 | 134.8 | -0.03% | 4,129 |
26/06/24 | 134.8 | -1.99% | 5,429 |
25/06/24 | 137.6 | +3.91% | 5,437 |
24/06/24 | 132.4 | -0.59% | 2,765 |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 05:18 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- NOV Stock